Dolmetsch Ricardo
Known title: President, R&DCIK: 0001825206
Associated companies
Transaction History
| QURE | ▼ Sell | Open Market | 5,841 | $44K | 9/18/2023 | View on chart |
| QURE | ▼ Sell | Open Market | 837 | $18K | 3/7/2023 | View on chart |
| QURE | ▼ Sell | Open Market | 6,944 | $136K | 2/27/2023 | View on chart |
| QURE | ▲ Buy | Grant | 46,700 | $0 | 2/23/2023 | View on chart |
| QURE | ▲ Buy | Grant | 2,920 | $0 | 2/20/2023 | View on chart |
| QURE | ▼ Sell | Open Market | 2,219 | $49K | 12/9/2022 | View on chart |
| QURE | ▲ Buy | Grant | 7,300 | $0 | 11/22/2022 | View on chart |
| QURE | ▼ Sell | Open Market | 1,484 | $25K | 2/28/2022 | View on chart |
| QURE | ▲ Buy | Grant | 54,683 | $0 | 2/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
QURE shares fall after Huntington data update and Barclays downgrade
Cedar Grove Capital released its Q3 2026 portfolio update, noting QURE holdings. The stock fell 5.9% after Huntington's gene therapy data was updated, prompting a Barclays downgrade to equal‑weight and a new price target of $28. The move comes amid a broader market pullback, with the shares near a 17.1 RSI and a support level of $44.06.
QURE shares fall after Huntington data update and Barclays downgrade. Cedar Grove Capital released its Q3 2026 portfolio update, noting QURE holdings. The stock fell 5.9% after Huntington's gene therapy data was updated, prompting a Barclays downgrade to equal‑weight and a new price target of $28. The move comes amid a broader market pullback, with the shares near a 17.1 RSI and a support level of $44.06.